Literature DB >> 19207785

Importance of heart rate during exercise for response to cardiac resynchronization therapy.

Alexander H Maass1, Sandra Buck, Wybe Nieuwland, Johan Brügemann, Dirk J van Veldhuisen, Isabelle C Van Gelder.   

Abstract

BACKGROUND: Cardiac resynchronization therapy (CRT) is an established therapy for patients with severe heart failure and mechanical dyssynchrony. Response is only achieved in 60-70% of patients.
OBJECTIVES: To study exercise-related factors predicting response to CRT.
METHODS: We retrospectively examined consecutive patients in whom a CRT device was implanted. All underwent cardiopulmonary exercise testing prior to implantation and after 6 months. The occurrence of chronotropic incompetence and heart rates exceeding the upper rate of the device, thereby compromising biventricular stimulation, was studied. Response was defined as a decrease in LVESV of 10% or more after 6 months.
RESULTS: We included 144 patients. After 6 months 86 (60%) patients were responders. Peak VO2 significantly increased in responders. Chronotropic incompetence was more frequently seen in nonresponders (21 [36%] vs 9 [10%], P = 0.03), mostly in patients in SR. At moderate exercise, defined as 25% of the maximal exercise tolerance, that is, comparable to daily life exercise, nonresponders more frequently went above the upper rate of the device (13 [22%] vs 2 [3%], P < 0.0001), most of whom were patients in permanent AF. Multivariate analysis revealed heart rates not exceeding the upper rate of the device during moderate exercise (OR 15.8 [3.3-76.5], P = 0.001) and nonischemic cardiomyopathy (OR 2.4 [1.0-5.7], P = 0.04) as predictive for response.
CONCLUSIONS: Heart rate exceeding the upper rate during moderate exercise is an independent predictor for nonresponse to CRT in patients with AF, whereas chronotropic incompetence is a predictor for patients in SR.

Entities:  

Mesh:

Year:  2009        PMID: 19207785     DOI: 10.1111/j.1540-8167.2008.01422.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  7 in total

1.  Cardiac resynchronisation therapy and the role of optimal device utilisation.

Authors:  S Buck; A H Maass; D J van Veldhuisen; I C Van Gelder
Journal:  Neth Heart J       Date:  2009-09       Impact factor: 2.380

Review 2.  How to improve outcomes: should we put more emphasis on programming and medical care and less on patient selection?

Authors:  Laszlo Buga
Journal:  Heart Fail Rev       Date:  2012-11       Impact factor: 4.214

3.  Exercise biology and medicine: innovative research to improve global health.

Authors:  Marcas M Bamman; Dan M Cooper; Frank W Booth; Eva R Chin; P Darrell Neufer; Scott Trappe; J Timothy Lightfoot; William E Kraus; Michael J Joyner
Journal:  Mayo Clin Proc       Date:  2014-02       Impact factor: 7.616

4.  Ventilatory gas exchange and early response to cardiac resynchronization therapy.

Authors:  Chul-Ho Kim; Lyle J Olson; Win K Shen; Yong-Mei Cha; Bruce D Johnson
Journal:  J Heart Lung Transplant       Date:  2015-06-10       Impact factor: 10.247

5.  Cardiac resynchronization in mild heart failure: all issues resolved? Editorial to "Cardiac resynchronization therapy in patients with mild heart failure: a systematic review and meta-analysis of randomized controlled trials" by Ronghui Tu et al.

Authors:  Alexander H Maass
Journal:  Cardiovasc Drugs Ther       Date:  2011-08       Impact factor: 3.727

6.  Cardiac resynchronization therapy-heart failure (CRT-HF) clinic: A novel model of care.

Authors:  Eiran Z Gorodeski; Christina Magnelli-Reyes; Laurie Ann Moennich; Adam Grimaldi; John Rickard
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

7.  Impact of closed loop stimulation on prognostic cardiopulmonary variables in patients with chronic heart failure and severe chronotropic incompetence: a pilot, randomized, crossover study.

Authors:  Joachim Proff; Béla Merkely; Roland Papp; Corinna Lenz; Peter Nordbeck; Christian Butter; Juergen Meyerhoefer; Michael Doering; Dean J MacCarter; Katharina Ingel; Thomas Thouet; Ulf Landmesser; Mattias J Roser
Journal:  Europace       Date:  2021-11-08       Impact factor: 5.214

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.